May 2026 in “Dermatologic Surgery” This study reports conflicting evidence on whether GLP-1 receptor agonists are associated with various forms of alopecia, suggesting dermatology practitioners should consider monitoring and counseling patients using these medications.
April 2026 in “Journal of Clinical Medicine” This review summarizes recent research into the effects of GLP-1 receptor agonists on skin processes, noting potential benefits for wound healing but also potential cosmetic concerns like facial fat loss and decreased collagen, highlighting the need for more clinical studies to clarify their dermatological impact.
October 2025 in “EMJ Dermatology” This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.
September 2025 in “Cureus” This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.
September 2025 in “Cureus” This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.
